GEN Exclusives

More »

GEN News Highlights

More »
Jan 8, 2008

NicOx to Receive €3M in Funding through One-Year Extension of Opthamology Deal with Pfizer

  • NicOx and Pfizer agreed to a one-year extension of a March 2006 ophthalmology collaboration. Pfizer thus will continue to have exclusively rights to apply NicOx’ nitric oxide-donating technology to drug discovery research in the field of ophthalmology.

    NicOx will receive 3 million in research funding in March 2008. Additionally, Pfizer now has the option to obtain an exclusive, worldwide license to develop and commercialize compounds resulting from the research program until May 2009.

    The agreement provides for total potential milestone payments in excess of 300 million. This amount includes 102 million that would arise from the successful development and launch of the first compound.

    Encouraging results have been observed for various compounds in in vitro and in vivo preclinical models of a prevalent eye disease, according to the firms.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »